In recent years, the chimeric antigen receptor (car) t-cell treatment sector has had exceptional growth, expected to continue in the coming years. Rising investments in research and development activities, the entry of new players, product innovation, technological breakthroughs, effective resource allocation, and growing competition among business rivals to expand its regional and customer base contribute to the industry's growth.
